Clinical Trial

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

TransCode Therapeutics and Quantum Leap are targeting hidden cancer cells with a novel RNA drug in a pivotal trial that could prevent colorectal cancer relapse.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

A breakthrough program at Children's Hospital of Philadelphia is redefining heart pumps as tools for recovery, not just a bridge to transplant.

The digital health giant now offers a 50+ cancer blood test, promising early detection. But experts caution on its limits and lack of FDA approval.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

A world-first trial for personalized mRNA vaccines offers new hope for children with aggressive brain tumors, a mission born from a father's own fight.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

Final Phase 1b data for Kodiak Sciences' KSI-101 suggests a potential breakthrough for macular edema, a condition lacking dedicated biologic therapies.